Thomas Shrader
Stock Analyst at BTIG
(2.90)
# 1,483
Out of 5,135 analysts
77
Total ratings
38.03%
Success rate
1.94%
Average return
Main Sectors:
Stocks Rated by Thomas Shrader
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DRUG Bright Minds Biosciences | Maintains: Buy | $147 | $83.50 | +76.05% | 4 | Feb 17, 2026 | |
| ANRO Alto Neuroscience | Maintains: Buy | $27 → $28 | $17.98 | +55.73% | 2 | Feb 17, 2026 | |
| DNLI Denali Therapeutics | Reiterates: Buy | $32 | $19.30 | +65.80% | 4 | Feb 6, 2026 | |
| IRD Opus Genetics | Reiterates: Buy | $7 | $3.83 | +82.77% | 2 | Jan 28, 2026 | |
| ABOS Acumen Pharmaceuticals | Maintains: Buy | $4 → $7 | $2.59 | +170.27% | 3 | Jan 27, 2026 | |
| NVAX Novavax | Reiterates: Buy | $19 | $8.78 | +116.52% | 1 | Jan 20, 2026 | |
| NRXP NRx Pharmaceuticals | Reiterates: Buy | $25 | $1.85 | +1,255.01% | 2 | Jan 15, 2026 | |
| IVVD Invivyd | Reiterates: Buy | $10 | $1.58 | +532.91% | 2 | Dec 23, 2025 | |
| BHVN Biohaven | Reiterates: Buy | $16 | $11.52 | +38.89% | 5 | Nov 18, 2025 | |
| COYA Coya Therapeutics | Maintains: Buy | $15 → $16 | $4.82 | +231.95% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $85 | $55.11 | +54.24% | 6 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $5.04 | +78.57% | 2 | Nov 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $39 | $31.44 | +24.05% | 2 | Nov 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $8 | $2.58 | +210.68% | 3 | Nov 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $48 → $23 | $7.48 | +207.49% | 2 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $2.00 | - | 4 | Oct 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $9 | $1.85 | +386.49% | 4 | Oct 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $7 → $14 | $8.22 | +70.32% | 1 | Oct 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $63 | $50.55 | +24.64% | 3 | Sep 29, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.43 | - | 3 | Jul 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $4 | $1.46 | +173.97% | 3 | Mar 24, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $16.99 | +1,077.16% | 1 | Oct 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $180 → $60 | $3.87 | +1,450.39% | 1 | Jul 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $7 | $5.14 | +36.19% | 2 | May 25, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $68 → $13 | $0.13 | +9,587.03% | 3 | Mar 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $51 | $1.22 | +4,080.33% | 1 | Apr 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $16 | $5.87 | +172.57% | 1 | Mar 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $3.44 | - | 1 | Feb 3, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 → $3 | $1.83 | +64.38% | 3 | Apr 3, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $397 → $346 | $195.01 | +77.43% | 3 | Feb 21, 2019 |
Bright Minds Biosciences
Feb 17, 2026
Maintains: Buy
Price Target: $147
Current: $83.50
Upside: +76.05%
Alto Neuroscience
Feb 17, 2026
Maintains: Buy
Price Target: $27 → $28
Current: $17.98
Upside: +55.73%
Denali Therapeutics
Feb 6, 2026
Reiterates: Buy
Price Target: $32
Current: $19.30
Upside: +65.80%
Opus Genetics
Jan 28, 2026
Reiterates: Buy
Price Target: $7
Current: $3.83
Upside: +82.77%
Acumen Pharmaceuticals
Jan 27, 2026
Maintains: Buy
Price Target: $4 → $7
Current: $2.59
Upside: +170.27%
Novavax
Jan 20, 2026
Reiterates: Buy
Price Target: $19
Current: $8.78
Upside: +116.52%
NRx Pharmaceuticals
Jan 15, 2026
Reiterates: Buy
Price Target: $25
Current: $1.85
Upside: +1,255.01%
Invivyd
Dec 23, 2025
Reiterates: Buy
Price Target: $10
Current: $1.58
Upside: +532.91%
Biohaven
Nov 18, 2025
Reiterates: Buy
Price Target: $16
Current: $11.52
Upside: +38.89%
Coya Therapeutics
Nov 13, 2025
Maintains: Buy
Price Target: $15 → $16
Current: $4.82
Upside: +231.95%
Nov 10, 2025
Reiterates: Buy
Price Target: $85
Current: $55.11
Upside: +54.24%
Nov 10, 2025
Reiterates: Buy
Price Target: $9
Current: $5.04
Upside: +78.57%
Nov 5, 2025
Reiterates: Buy
Price Target: $39
Current: $31.44
Upside: +24.05%
Nov 4, 2025
Reiterates: Buy
Price Target: $8
Current: $2.58
Upside: +210.68%
Oct 22, 2025
Maintains: Buy
Price Target: $48 → $23
Current: $7.48
Upside: +207.49%
Oct 22, 2025
Downgrades: Neutral
Price Target: n/a
Current: $2.00
Upside: -
Oct 15, 2025
Reiterates: Buy
Price Target: $9
Current: $1.85
Upside: +386.49%
Oct 13, 2025
Maintains: Buy
Price Target: $7 → $14
Current: $8.22
Upside: +70.32%
Sep 29, 2025
Reiterates: Buy
Price Target: $63
Current: $50.55
Upside: +24.64%
Jul 1, 2025
Downgrades: Neutral
Price Target: n/a
Current: $1.43
Upside: -
Mar 24, 2025
Maintains: Buy
Price Target: $5 → $4
Current: $1.46
Upside: +173.97%
Oct 3, 2023
Initiates: Buy
Price Target: $200
Current: $16.99
Upside: +1,077.16%
Jul 28, 2023
Maintains: Buy
Price Target: $180 → $60
Current: $3.87
Upside: +1,450.39%
May 25, 2023
Maintains: Buy
Price Target: $15 → $7
Current: $5.14
Upside: +36.19%
Mar 28, 2023
Maintains: Buy
Price Target: $68 → $13
Current: $0.13
Upside: +9,587.03%
Apr 20, 2021
Initiates: Buy
Price Target: $51
Current: $1.22
Upside: +4,080.33%
Mar 8, 2021
Initiates: Buy
Price Target: $16
Current: $5.87
Upside: +172.57%
Feb 3, 2021
Downgrades: Neutral
Price Target: n/a
Current: $3.44
Upside: -
Apr 3, 2020
Maintains: Buy
Price Target: $4 → $3
Current: $1.83
Upside: +64.38%
Feb 21, 2019
Downgrades: Hold
Price Target: $397 → $346
Current: $195.01
Upside: +77.43%